[Congressional Bills 117th Congress]
[From the U.S. Government Publishing Office]
[H.R. 1193 Reported in Senate (RS)]
<DOC>
Calendar No. 443
117th CONGRESS
2d Session
H. R. 1193
_______________________________________________________________________
IN THE SENATE OF THE UNITED STATES
December 9, 2021
Received
May 25, 2022
Read twice and referred to the Committee on Health, Education, Labor,
and Pensions
July 12, 2022
Reported by Mrs. Murray, with an amendment
[Strike out all after the enacting clause and insert the part printed
in italic]
_______________________________________________________________________
AN ACT
To amend title IV of the Public Health Service Act to direct the
Director of the National Institutes of Health, in consultation with the
Director of the National Heart, Lung, and Blood Institute, to establish
a program under which the Director of the National Institutes of Health
shall support or conduct research on valvular heart disease, and for
other purposes.
Be it enacted by the Senate and House of Representatives of the
United States of America in Congress assembled,
<DELETED>SECTION 1. SHORT TITLE.</DELETED>
<DELETED> This Act may be cited as the ``Cardiovascular Advances in
Research and Opportunities Legacy Act''.</DELETED>
<DELETED>SEC. 2. GRANTS FOR VALVULAR HEART DISEASE RESEARCH.</DELETED>
<DELETED> Subpart 2 of part C of title IV of the Public Health
Service Act (42 U.S.C. 285b et seq.) is amended by inserting after
section 424C (42 U.S.C. 285b-7c) the following:</DELETED>
<DELETED>``SEC. 424D. GRANTS FOR VALVULAR HEART DISEASE
RESEARCH.</DELETED>
<DELETED> ``(a) In General.--The Director of the National Institutes
of Health, in consultation with the Director of the Institute, shall
support or conduct research regarding valvular heart disease.</DELETED>
<DELETED> ``(b) Support Guidelines.--The distribution of funding
authorized under subsection (a) may be used to pursue the following
outcomes:</DELETED>
<DELETED> ``(1) Using precision medicine and advanced
technological imaging to generate data on individuals with
valvular heart disease.</DELETED>
<DELETED> ``(2) Identifying and developing a cohort of
individuals with valvular heart disease and available
data.</DELETED>
<DELETED> ``(3) Corroborating data generated through
clinical trials to develop a prediction model to distinguish
individuals at high risk for sudden cardiac arrest or sudden
cardiac death from valvular heart disease.</DELETED>
<DELETED> ``(4) For other outcomes needed to acquire
necessary data on valvular heart disease.</DELETED>
<DELETED> ``(c) Mitral Valve Prolapse Workshop.--Not later than one
year after the date of the enactment of this section, the Director of
the Institute shall convene a workshop composed of subject matter
experts and stakeholders to identify research needs and opportunities
to develop prescriptive guidelines for treatment of individuals with
mitral valve prolapse.</DELETED>
<DELETED> ``(d) Authorization of Appropriations.--For the purpose of
carrying out this section, there is authorized to be appropriated
$20,000,000 for each of fiscal years 2022 through 2026.''.</DELETED>
<DELETED>SEC. 3. PROGRAMS OF CENTERS FOR DISEASE CONTROL AND
PREVENTION.</DELETED>
<DELETED> Part B of title III of the Public Health Service Act (42
U.S.C. 243 et seq.) is amended by inserting after section 312 the
following section:</DELETED>
<DELETED>``SEC. 312A. PREVENTION OF SUDDEN CARDIAC DEATH AS A RESULT OF
VALVULAR HEART DISEASE.</DELETED>
<DELETED> ``(a) In General.--The Secretary, acting through the
Director of the Centers for Disease Control and Prevention, may carry
out projects to increase education, awareness, or diagnosis of valvular
heart disease and to reduce the incidence of sudden cardiac death
caused by valvular heart disease. Such projects may be carried out by
the Secretary directly or through awards of grants or contracts to
public or nonprofit private entities. The Secretary may directly (or
through such awards) provide technical assistance with respect to the
planning, development, and operation of such projects.</DELETED>
<DELETED> ``(b) Certain Activities.--Upon availability of applicable
data, projects carried out under subsection (a) may include--</DELETED>
<DELETED> ``(1) continuing the activities at the Division
for Heart Disease and Stroke Prevention, including those
related to valvular heart disease;</DELETED>
<DELETED> ``(2) broadening the awareness of the public
concerning the risk factors for, the symptoms of, and the
public health consequences of valvular heart disease;
and</DELETED>
<DELETED> ``(3) enhancing surveillance of out-of-hospital
cardiac arrests to improve patient outcomes.</DELETED>
<DELETED> ``(c) Grant Prioritization.--The Secretary may, in
awarding grants or entering into contracts pursuant to subsection (a),
give priority to entities seeking to carry out projects that target
populations most impacted by valvular heart disease.</DELETED>
<DELETED> ``(d) Coordination of Activities.--The Secretary shall
ensure that activities under this section are coordinated, as
appropriate, with other agencies of the Public Health Service that
carry out activities regarding valvular heart disease.</DELETED>
<DELETED> ``(e) Best Practices.--The Secretary, acting through the
Director of the Centers for Disease Control and Prevention, shall--
</DELETED>
<DELETED> ``(1) collect and analyze the findings of research
conducted with respect to valvular heart disease; and</DELETED>
<DELETED> ``(2) taking into account such findings, publish
on the website of the Centers for Disease Control and
Prevention best practices for physicians and other health care
providers who provide care to individuals with valvular heart
disease.''.</DELETED>
SECTION 1. SHORT TITLE.
This Act may be cited as the ``Cardiovascular Advances in Research
and Opportunities Legacy Act''.
SEC. 2. HHS VALVULAR HEART DISEASE ACTIVITIES.
(a) In General.--The Secretary of Health and Human Services
(referred to in this section as the ``Secretary'') shall, as
appropriate, continue activities related to research, education, and
awareness of valvular heart diseases.
(b) NIH Research Related to Valvular Heart Diseases.--
(1) In general.--The Director of the National Institutes of
Health, in consultation with the Director of the National
Heart, Lung, and Blood Institute, may support or conduct
research regarding valvular heart diseases.
(2) Support further research.--In order to improve
information on, and understanding of, causation and risk
factors for valvular heart diseases, research conducted or
supported under this subsection for such diseases may include
the following:
(A) Use of advanced technological imaging and other
relevant methods to generate data related to valvular
heart diseases.
(B) Assessing potential risk factors for sudden
cardiac arrest or sudden cardiac death from valvular
heart diseases.
(C) Other activities, as appropriate, in order to
improve the availability of information on, and advance
research related to, valvular heart diseases.
(3) Mitral valve prolapse workshop.--Not later than one
year after the date of enactment of this Act, the Director of
the National Heart, Lung, and Blood Institute shall, as
appropriate, convene a workshop composed of subject matter
experts and stakeholders to identify research needs and
opportunities to develop recommendations for the identification
and treatment of individuals with mitral valve prolapse,
including such individuals who may be at risk for sudden
cardiac arrest or sudden cardiac death.
(c) Prevention Activities to Improve Awareness of Sudden Cardiac
Death as a Result of Valvular Heart Diseases.--
(1) In general.--The Secretary may carry out activities to
increase education and awareness of valvular heart diseases in
order to reduce the incidence of sudden cardiac death caused by
such diseases. The Secretary may--
(A) award grants or contracts to public or
nonprofit private entities to carry out activities
under this subsection; and
(B) may directly, or through grants or contracts,
provide technical assistance with respect to such
activities.
(2) Certain activities.--Upon availability of applicable
data, projects carried out under paragraph (1) may include--
(A) continuing activities at the Centers for
Disease Control and Prevention related to valvular
heart diseases;
(B) improving the awareness of the public
concerning any risk factors for, the symptoms of, and
the public health impact of, valvular heart diseases;
and
(C) improving the availability of public health
data and information, as appropriate, regarding cardiac
arrests related to valvular heart diseases.
(3) Grant prioritization.--The Secretary may, in awarding
grants or entering into contracts pursuant to paragraph (1),
give priority to entities seeking to carry out projects for
populations most impacted by valvular heart diseases.
(4) Coordination of activities.--The Secretary shall, as
appropriate, ensure that activities under this section are
coordinated with other agencies and offices of the Department
of Health and Human Services that carry out activities
regarding valvular heart diseases.
(5) Best practices.--The Secretary shall, as applicable and
appropriate, identify and disseminate best practices for
relevant health care providers related to valvular heart
diseases.
(d) Authorization of Appropriations.--For purposes of carrying out
this section, there are authorized to be appropriated such sums as may
be necessary for each of fiscal years 2023 through 2027.
Calendar No. 443
117th CONGRESS
2d Session
H. R. 1193
_______________________________________________________________________
AN ACT
To amend title IV of the Public Health Service Act to direct the
Director of the National Institutes of Health, in consultation with the
Director of the National Heart, Lung, and Blood Institute, to establish
a program under which the Director of the National Institutes of Health
shall support or conduct research on valvular heart disease, and for
other purposes.
_______________________________________________________________________
July 12, 2022
Reported with an amendment